Asked about the sequential decline in Pharmacy segment gross margin from Q1 to Q2, noting historical flatness.

Management stated Q2 margins were healthy and in line with expectations, attributing the sequential difference to typical Q1 seasonality. GP per script was up in Q2 when normalized. “Yes, Ann, the margins in Q2 were very healthy again and completely in line with our expectations. We had seasonality in Q1 of this year, which is very typical, and typical for your gross margin to be a little bit higher in Q1 versus Q2 for a variety of reasons.”

Inquired about growth rates in acute vs. chronic infusion and momentum/investments in chronic infusion.

Overall Infusion volume up over 20% YoY. Chronic infusion volume up close to 20% YoY, with new initiatives like white glove concierge programs improving conversion rates. Continued investment in capabilities, infrastructure, AI, and new leadership. “I can say that our achieved volume year-over-year was up over 20%, which is what some 7 to 8x what that market grows at. So some of our investments really pay off.”

Asked about pharmacy sourcing strategies and the potential impact of generic tariffs.

Sourcing is a decade-long focus, leveraging scale for external partners. Generic tariffs are not currently impacting the company, with any potential impact pushed to 2028. Management is flexible in purchasing and not concerned about long-term growth. “We're pleased that the Trump administration has pushed any potential tariffs on generics to 2028. We continue to be flexible, as Jon mentioned, in our purchasing contracts.”

BTSG

BrightSpring (BTSG) Q2 FY26 earnings call: guidance and Q&A

Earnings call· Jun 2026 (Q2 FY26)· Health Care· Jul 31, 2026

Source: earnings call transcript

Executive summary

BrightSpring Q2 FY26 — Strong Revenue and EBITDA Growth Driven by Specialty Pharmacy and Provider Services

BrightSpring Health Services reported a strong second quarter, surpassing expectations with robust revenue and EBITDA growth across its Pharmacy Solutions and Provider Services segments. The company demonstrated effective operational execution, leveraging scale and technology to drive profitability and reduce leverage. Despite ongoing IRA headwinds impacting Home and Community Pharmacy revenue, management remains confident in its full-year guidance and strategic growth initiatives, including disciplined M&A and expansion into new markets.

Highlights

Total company revenue grew 23% year-over-year to $3.9 billion, exceeding baseline expectations.
Adjusted EBITDA increased 44% year-over-year to $206 million, with an 80 basis point margin improvement to 5.3%.
Pharmacy Solutions revenue grew 22% to $3.4 billion, driven by 30% growth in Specialty and Infusion business.
Provider Services revenue grew 30% to $466 million, with Home Health Care revenue up 51%.
Leverage reduced to 2.15x as of June 30, 2026, with ratings upgrades from Moody's and S&P.

Concerns

Home and Community Pharmacy revenue declined 8% year-over-year due to a $50 million impact from the IRA and the exit of certain uneconomic customers.
The IRA is expected to result in a total revenue impact of approximately $200 million for Home and Community Pharmacy in FY26, with a $15 million EBITDA impact.
Specialty Pharmacy faces a $175 million revenue headwind from the IRA in FY26.

Guidance & targets

Category	Target	Timeline	Confidence
Total Revenue	$15.1 billion to $15.425 billion high materiality	FY26	High
Pharmacy Solutions Revenue	$13.2 billion to $13.5 billion medium materiality	FY26	High
Provider Services Revenue	$1.9 billion to $1.925 billion medium materiality	FY26	High
Total Adjusted EBITDA	$820 million to $845 million high materiality	FY26	High
Operating Cash Flow	approximately $600 million medium materiality	FY26	High
Leverage Ratio	below 2x high materiality	FY26	High
Amedisys and LHC assets EBITDA contribution	approximately $35 million medium materiality	FY26	High
IRA impact on Home and Community Pharmacy revenue	approximately $45 million medium materiality	Q3 FY26 and Q4 FY26	High
IRA impact on Home and Community Pharmacy revenue	approximately $200 million medium materiality	FY26	High
IRA impact on Home and Community Pharmacy EBITDA	$15 million medium materiality	FY26	High
IRA impact on Specialty Pharmacy revenue	$175 million medium materiality	FY26	High
IRA impact on Home and Community Pharmacy revenue	about 50% of 2026 impact medium materiality	FY27	Medium

Segment performance

Segment	Revenue	YoY	QoQ	Margin
Pharmacy Solutions Continued business momentum in Specialty and Infusion driven by branded oncology LDD portfolio, expansion into rare/orphan therapies, and solid contribution from generic scripts. Home and Community Pharmacy volume and revenue impacted by IRA and customer exits, but profitability improved due to automation and technology investments. Adjusted EBITDA: $180 millionAdjusted EBITDA growth YoY: 44%Specialty and Infusion revenue: $2.9 billionSpecialty and Infusion revenue growth: 30%Specialty and Infusion script growth: 31%LDDs added in Q2: 2Total LDDs: 155LDDs launched YTD: 12 (4 exclusive, 8 ultra-narrow)Home and Community Pharmacy revenue: $540 millionHome and Community Pharmacy revenue growth YoY: -8%	$3.4 billion	22%	—	Adjusted EBITDA margin of 5.3%
Provider Services Strong performance driven by need for services, volume growth above industry levels, de novo investments, and successful integration of Amedisys and LHC branches. Hospice, Rehab Care, and Personal Care also showed strong quality metrics and growth. Adjusted EBITDA: $75 millionAdjusted EBITDA growth YoY: 33%Home Health Care revenue: $278 millionHome Health Care revenue growth YoY: 51%Amedisys and LHC branches revenue contribution: $78 millionAmedisys and LHC branches adjusted EBITDA contribution: $8 millionRehab Care revenue: $82 millionRehab Care revenue growth YoY: 12%Personal Care revenue: $107 millionPersonal Care revenue growth YoY: 7%	$466 million	30%	—	Adjusted EBITDA margin of 16.1%

BTSG operating KPIs by quarter

BTSG operating KPIs stated on its earnings calls, by fiscal quarter
KPI	Mar 2026 Q1 FY26	This call Jun 2026 Q2 FY26	Change vs prior quarter
LDDs	153 We continue to see strong volume performance from both brand LDDs and generics, and we added 4 exclusive and UltraAR LDDs to our portfolio in the first quarter, bringing our total number of LDDs to 153. Source: earnings call transcript	155 During the quarter, we added 2 ultra-narrow network LDDs to our portfolio bringing the total number of LDDs to 155. Source: earnings call transcript	+1.3%

Operating figures the company stated on at least two of the calls shown, checked against each call's transcript. Click a figure to read the sentence. A dash means it was not stated that quarter.

Deals & partnerships

Amedisys and LHC Integration of Home Health branches

Integration going well, all branches now on home-based system.

Risks & headwinds

IRA impact on Home and Community Pharmacy revenue FY26

$50 million impact in Q2 FY26; expected $45 million in each remaining quarter of FY26, totaling $200 million for FY26.

Mitigation:Internal operational process improvements, deployment of new technologies, payer contracting, regulatory advocacy.

IRA impact on Specialty Pharmacy revenue FY26

$175 million revenue headwind for FY26.

Mitigation:No EBITDA impact expected; internal operational adjustments.

Potential generic tariffs Potential impact pushed to 2028.

Not currently impacting the company.

Mitigation:Flexible purchasing contracts, monitoring closely, not seen as worrisome for long-term growth.

What to watch in Q3 FY26

Home and Community Pharmacy IRA impact

next quarter

Current $50 million revenue impact in Q2 FY26

Target Approximately $45 million revenue impact in Q3 FY26

Why it matters

To track the ongoing financial headwind from the IRA on this segment's revenue.

On the IRA impact for the balance of the year, we continue to see a revenue impact at Home and Community Pharmacy of approximately $45 million in each of the remaining quarters in 2026, bringing the total year IRA impact to Home and Community pharmacy revenue of approximately $200 million.

Find out whether BTSG delivers this. Inve re-checks your case every morning.

Q&A highlights

Inquired about the contribution of generic Revlimid to growth and asked about the increase in corporate expenses.

Management clarified Revlimid has been generic for years and had no recent impact. Corporate expense increase was due to key hires and investments in AI/automation technology projects, with benefits expected later in the year or early next year.

“From a corporate standpoint, Charles, we did see an increase as we continue to increase some investments across key hires, including some key hires we have in a couple of different business roles as well as corporate leaders that we're really excited about that are going to help drive value. We also did continue to invest in AI and automation technology projects throughout the quarter.”

asked by Charles Rhyee · answered by Jennifer Phipps

2 min read 7 chapters

Detailed narrative

Operational Excellence and Technology Investment

BrightSpring continues to invest in and progress on key clinical, HR, and operational systems, leveraging new automation and AI tools in areas such as hiring, onboarding, intake, documentation, medication reviews, and patient care plans. The company has seen almost 300 employees receive Lean Sigma certification, completing Lean projects across the organization to institutionalize lean business processes and drive efficiency.

Strategic Growth Drivers

The company's strategy is aligned with secular trends in U.S. healthcare, focusing on strong execution, thoughtful innovation, and continuous improvement. This includes expanding into adjacent and new markets, executing preferred MA and ACO contracts, and making de novo investments. These efforts, combined with leading quality results, are driving volume growth above industry levels, particularly in Home Health Care.

Specialty and Infusion Business Momentum

The Specialty and Infusion business delivered strong performance with 30% revenue growth and 31% script growth, driven by the branded oncology LDD portfolio. The company is leveraging its capabilities to expand into other targeted therapeutic areas, including rare, orphan, and complex therapies, securing noteworthy partnership wins. In Q2, 2 ultra-narrow network LDDs were added, bringing the total to 155, with 12 LDDs launched year-to-date.

Home and Community Pharmacy Optimization

Despite a revenue impact from the IRA and the strategic exit of certain uneconomic skilled nursing customers, the Home and Community Pharmacy business improved its profitability year-over-year. This was achieved through continued investment in automation and technology to enhance efficiency and service across its scaled national footprint, serving growing end markets like assisted living, behavioral, hospice, and skilled nursing.

Provider Services Integration and Quality

The integration of acquired Amedisys and LHC branches into Home Health has progressed extremely well, particularly in HR and IT, with nearly 95% of branches maintaining 4-star or better ratings. Hospice services continue to demonstrate industry-leading quality metrics and strong census growth, while Rehab Care and Personal Care also show consistent performance and high patient satisfaction scores.

Capital Allocation and M&A Strategy

BrightSpring maintains a full and robust M&A pipeline, focusing on disciplined execution of tuck-in acquisitions and geographical expansions that meet strategic objectives and offer accretive value. The company leverages its scale and operational capabilities to integrate these deals, aiming to increase the frequency of smaller tuck-ins while remaining disciplined on valuations for larger transactions, especially given its improved balance sheet and strong operating cash flow.

Regulatory Environment and Advocacy

CMS released preliminary rates for home health services for calendar year 2027, which include a positive annual payment update, marking the first such upward adjustment in several years. BrightSpring continues to engage with CMS and Congress, advocating for the positive health outcomes and lower Medicare cost profile associated with high-quality home health services.

Summary of the company's earnings call; see how call summaries are prepared. Not investment advice.